aTyr Pharma (ATYR) AI Stock Analysis

• Market Cap: $75.99M
• Dividend Yield: N/A
• Average Volume (3M): 2.96M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: -19.15%
• EPS Growth: 10.90%
• Country: US
• Employees: 56
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 97,986,630
• 10 Day Avg. Volume: 2,005,197
• 30 Day Avg. Volume: 2,963,218
• PEG Ratio: 0.49
• Price to Book (P/B): 3.84
• Price to Sales (P/S): 1143.94
• P/FCF Ratio: -3.89
• Enterprise Value/Market Cap: -0.10
• Enterprise Value/Revenue: -41.83
• Enterprise Value/Gross Profit: 0.23
• Enterprise Value/Ebitda: 0.10
• 1Y Price Target: $5.75
• Price Target Upside: 637.18% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 8
• EPS Forecast (FY): -0.81
• Revenue Forecast (FY): $106.36K

• Rating: 39 Underperform
• Price Target: $0.50 ▼(-35.90% Downside)

aTyr Pharma's overall stock score is primarily impacted by its poor financial performance and valuation, both scoring at the lowest end due to ongoing losses and negative cash flows. The technical analysis indicates a bearish trend, and the Nasdaq deficiency notice adds further risk, contributing to a low overall score.

Positive Factors

Strong Equity Position

A strong equity position provides aTyr Pharma with a solid financial foundation, offering resilience against financial volatility and supporting long-term strategic investments.

Proprietary Platform

aTyr Pharma's proprietary platform offers a competitive edge in developing innovative therapies, potentially leading to breakthrough treatments and sustainable revenue streams.

Manageable Debt Levels

Low debt levels reduce financial risk and interest burden, allowing aTyr Pharma to focus resources on R&D and strategic growth initiatives.

Negative Factors

Declining Revenue

Declining revenue highlights challenges in product adoption or market penetration, potentially impacting long-term growth and financial sustainability.

Negative Cash Flow

Negative cash flow indicates operational inefficiencies and may limit aTyr Pharma's ability to fund new projects or withstand economic downturns, posing long-term financial risks.

Nasdaq Deficiency Notice

The Nasdaq deficiency notice poses a risk of delisting, which could limit access to capital markets and negatively impact investor confidence and stock liquidity.

aTyr Pharma Business Overview & Revenue Model

Company Description

aTyr Pharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for rare diseases and immunological disorders. The company operates primarily in the biotechnology sector and is known for its proprietary platform that leverages naturally occurring proteins to create targeted treatments. aTyr's lead product candidates are based on its research into the physiological role of tRNA synthetases and their potential therapeutic applications, particularly in the fields of neuromuscular and pulmonary diseases.

How the Company Makes Money

aTyr Pharma generates revenue primarily through the development and commercialization of its therapeutic products. The company may receive funding from grants, collaborations, and partnerships with larger pharmaceutical entities that provide financial support in exchange for rights to develop and market certain products. Additionally, aTyr can earn revenue through milestone payments associated with the successful advancement of its drug candidates through clinical trials and regulatory approvals. Another potential revenue stream includes royalties from sales of partnered products, once they are commercialized.

aTyr Pharma Financial Statement Overview

Summary

aTyr Pharma faces significant financial challenges, characterized by declining revenue, ongoing losses, and negative cash flows. The company maintains a strong equity position and manageable debt levels, but the consistent lack of profitability and cash flow generation presents risks that need addressing to ensure long-term viability.

Income Statement

aTyr Pharma's income statement shows significant challenges with sustained negative profitability. The gross profit margin was 100% in 2024 due to minimal revenue, but the company has a consistent negative net profit margin due to high expenses outweighing revenue, with a net income of -$64 million in 2024. Revenue growth was negative at -33.43% from 2023 to 2024, indicating a decline in sales. The EBIT and EBITDA margins are both negative, reflecting ongoing operational losses.

Balance Sheet

The balance sheet shows a moderate financial position for aTyr Pharma. The debt-to-equity ratio is relatively low at 0.19, suggesting manageable leverage. However, the return on equity (ROE) is negative due to substantial net losses impacting shareholder value. The equity ratio stands at 72.33%, indicating a strong equity position relative to total assets.

Cash Flow

Cash flow analysis for aTyr Pharma reveals ongoing operational cash deficits, with an operating cash flow of -$69 million in 2024. The free cash flow growth rate is negative at -84.64%. The operating cash flow to net income ratio is slightly above 1, indicating operating losses are closely aligned with net income losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	190.00K	235.00K	353.00K	10.39M	0.00	10.46M
Gross Profit	-34.17M	235.00K	353.00K	8.69M	-1.30M	-6.84M
EBITDA	-76.54M	-66.37M	-52.18M	-44.71M	-32.47M	-14.64M
Net Income	-75.12M	-64.02M	-50.39M	-45.34M	-33.77M	-16.22M
Balance Sheet
Total Assets	106.65M	96.83M	120.65M	95.79M	115.54M	38.73M
Cash, Cash Equivalents and Short-Term Investments	90.20M	72.13M	98.17M	66.15M	107.91M	31.69M
Total Debt	12.36M	13.28M	15.10M	11.53M	1.38M	2.24M
Total Liabilities	26.61M	27.00M	30.18M	24.50M	6.41M	7.24M
Stockholders Equity	80.23M	70.02M	90.66M	71.46M	109.30M	31.65M
Cash Flow
Free Cash Flow	-62.99M	-69.18M	-37.44M	-43.53M	-33.27M	-15.50M
Operating Cash Flow	-62.92M	-69.12M	-33.22M	-41.89M	-33.08M	-15.30M
Investing Cash Flow	-27.58M	17.23M	-20.13M	47.24M	-91.57M	6.90M
Financing Cash Flow	84.98M	39.86M	66.23M	5.45M	110.03M	16.14M

aTyr Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATYR, the sentiment is Negative. The current price of 0.78 is above the 20-day moving average (MA) of 0.75, below the 50-day MA of 0.85, and below the 200-day MA of 3.27, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 44.92 is Neutral, neither overbought nor oversold. The STOCH value of 54.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATYR.

aTyr Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	60 Neutral	$76.47M	-0.69	-49.78%	―	-82.16%	14.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATYR	39 Underperform	$75.99M	―	-103.22%	―	-19.15%	10.90%
OKYO	38 Underperform	$77.48M	―	―	―	―	―
CNTX	37 Underperform	$95.55M	―	-33.68%	―	―	69.30%
PRLD	35 Underperform	$99.61M	-0.99	-103.99%	―	250.00%	15.15%

aTyr Pharma Corporate Events

aTyr Pharma Receives Nasdaq Deficiency Notice

On December 4, 2025, aTyr Pharma, Inc. received a deficiency notice from Nasdaq, indicating that its stock price had fallen below the required $1.00 per share for 30 consecutive business days. This notice does not immediately affect the company’s listing, and aTyr Pharma has until June 2, 2026, to comply with the minimum bid price requirement. The company is exploring options to regain compliance, including a potential reverse stock split, to avoid delisting.

aTyr Pharma Reveals Phase 3 Study Results

On September 15, 2025, aTyr Pharma announced the topline results from its Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis. The study did not meet its primary endpoint of reducing the mean daily oral corticosteroid dose, but showed clinical improvement in the King’s Sarcoidosis Questionnaire-Lung score and maintained lung function. The company plans to engage with the FDA to discuss the results and determine the next steps for efzofitimod’s development, highlighting its potential activity across multiple efficacy endpoints.